You may find more results for this query on our sister sites: GenomeWeb and 360Dx.
The latest news on next-generation sequencing.
The Sentinel trial will enroll up to 100,000 patients with early-stage tumors to evaluate Strata's investigational liquid biopsy assay.
Using its xT sequencing platform, Tempus will create a companion test to identify patients eligible for treatment with A2's cell-based LOH-targeted therapy.
The drugmaker is supporting access to NGS testing in these countries to identify lung and pancreatic cancer patients with NRG1 fusions who can join its study.
The partners will use Adaptive's ImmunoSeq T-Map technology to analyze immune response to cancer antigens across AstraZeneca's oncology portfolio.
The firm also provided preliminary revenues of $950 million for Q4 and reinstated guidance of $3.79 billion to $3.88 billion for 2021.
The firms will use Resolution's ctDx liquid biopsy technology to find non-small cell lung cancer patients who may benefit from Mirati's KRAS G12C inhibitor therapy.
Although a record number of new precision oncology drugs came to market, the pandemic further exposed access gaps that the field is focused on mitigating.
Sema4 will use its next-generation sequencing testing services to identify patients with solid tumors harboring NRG1 fusions for Merus' Phase I/II drug trial.
The partners are starting by testing patients with colorectal and thyroid cancers using the 648-gene Tempus xT assay, but could expand to other areas in the future.
In a retrospective analysis, ALL patients tested with NGS were less likely to achieve MRD-negative status than when tested with flow cytometry.